Clinical efficacy of Danhong Injection on cardiac syndrome X
HU Guo-ling
BAI Xiu-ping
HOU Xiao-lu
Abstract：Objective To observe the short-term clinical efficacy of routine treatment combining Danhong Injection on cardiac syndrome X (CSX). Methods The patients (n=60) were randomly divided into observation group and control group (each n=30). The control group was treated with routine treatment, and observation group was treated with routine treatment combining Danhong Injection for 10 d. The clinical efficacy was observed before and after treatment, including attack of angina, changes of electrocardiogram (ECG) and treadmill exercise test (TET), and levels of serum endothelin-1 (ET-1), thrombomodulin (TM) and E-selectin (Es). Results The total effective rate of chest pain relief was 93.33%in observation group and 73.33%in control group, and total effective rate of ECG relief was 83.33%in observation group and 56.67%in control group (P<0.05). In TET, the total exercise time was (486.9±83.0) s in observation group and (438.3±85.6) s in control group, and the time from exercise beginning to ST-segment lowered by 1 mm was (351.9±69.2) s in observation group and (310.7±79.2) s in control group (P<0.05). The levels of ET-1, TM and Es had no statistical difference between 2 groups before treatment (P>0.05). After treatment, ET-1 (54.58±7.95) ng/L vs. (76.21±1.78) ng/L, TM (7.01±1.49)μg/L vs. (11.10±1.68)μg/L and Es (7.50±2.71) ng/mL vs. (10.71±3.56) ng/mL had statistical difference between 2 groups (P<0.01). There were no adverse reactions observed in 2 groups. Conclusion Danhong Injection can relieve the clinical symptoms and reduce levels of ET-1, TM and Es in patients with CSX.
Keywords：Danhong InjectionCoronary microcirculationCardiac syndrome XEndothelial functionInflammation
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 558-561 )